Clinical Trials Logo

Reduced Ejection Fraction clinical trials

View clinical trials related to Reduced Ejection Fraction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05420285 Recruiting - Heart Failure Clinical Trials

Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction

ICARD
Start date: June 26, 2022
Phase: Phase 2
Study type: Interventional

Gliflozins have demonstrated a beneficial effect in terms of incident heart failure and related events in patients with or without diabetes. The clinical trial ICARD is an exploratory study that aims to evaluate the cardiometabolic mechanistic effects on the myocardium of dapagliflozin in heart failure with reduced ejection fraction. Deep phenotyping of cardiac and vascular function will be performed using MRI. Myocardial tissue characterization will be based on MRI and FDG-PET for glucose metabolism assessment. Liver steatosis and fibrosis will simultaneously be assessed.

NCT ID: NCT03875183 Recruiting - Heart Failure Clinical Trials

Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

TRACER-HF
Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).

NCT ID: NCT02018029 Recruiting - Heart Failure Clinical Trials

Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers

PREFAC-CRT
Start date: March 2013
Phase: N/A
Study type: Observational

Cardiac resynchronization therapy (CRT) is one of the lastest recommended treatments in patients with refractory symptomatic chronic heart failure with reduced ejection fraction (HFREF). Despite clear guidelines 20 to 40 % of implanted patients are not clinically ameliorated. They are called the "non responders". Patient selection seams to be one of the key to improve the efficiency of CRT. This protocol try to assess positive predictive factors to CRT by a multimodal approach.